TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin
Open Access
- 1 November 1995
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 270 (46), 27531-27537
- https://doi.org/10.1074/jbc.270.46.27531
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair.Genes & Development, 1994
- Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progressionCell, 1993
- Atomic Structures of the Human Immunophilin FKBP-12 Complexes with FK506 and RapamycinJournal of Molecular Biology, 1993
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991
- Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?The Journal of Experimental Medicine, 1991
- Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.Proceedings of the National Academy of Sciences, 1990
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989
- A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformaion of Escherichia coliGene, 1987